Updated January 26, 2013.
On Friday, January 25, 2013, an advisor to the management of the United States Food and Drug Administration committee voted 19-10 to recommend the removal of drug hydrocodone as Vicodin, Lortab, Norco and Category II schedule of controlled substances. If the FDA follows the recommendation of the Committee and hydrocodone combination drugs your current schedule III of Annex II moves prescribing practices would be more restricted. Many arthritis patients with hydrocodone combination of medications to control pain.
Drugs and other controlled substances under the Controlled Substances Act as substances are divided into five schedules. The classification, whether a drug or substance has a currently accepted medical use in treatment in the United States, its potential for abuse and dependence can cause if misused based. Here's a look at five hours.
The passage of Annex III of the Second refuse medication for a period of six months, to prescribe hydrocodone combination. Doctors would not be able to fax or phone a prescription for these drugs. Require Schedule II drugs either written for a three-month supply of prescription drugs.
Those who fight to prevent drug abuse and lead the fatal consequences, sitting from opioid abuse on the one side of this question. It has seen an epidemic problem that we as a society need and address. However, it is on the other side of the issue can not be ignored - appropriate for people with chronic pain such as arthritis access to opioids. If implemented, the change in the schedule for the combination of drugs and similar products hydrocodone unnecessary burden for people who need medication to function in their daily lives restrictions? Have doctors change due to prescription drugs to move away, thereby providing access for people with chronic pain problems? Neglected the needs of patients with chronic pain due to drug abuse to fight or put to sleep has become an urgent battle? Or is it reasonable proposal? What do you think? In from.
Related Articles:
Follow me:
Facebook | Twitter | Forums | Newsletter
Photo by David Sucsy (iStockphoto)
No comments:
Post a Comment